HOME > INVESTOR > ARCHIVES > PRESS RELEASE
December 2006
Lupin and Cornerstone End Development Agreement
Lupin's US Subsidiary and Chester Valley Pharmaceuticals decide to end promotion agreement
Lupin gets tentative US FDA approval for Trandolapril
Lupin gets DCGI approval to conduct Phase III clinical trials for Migraine NCE


October 2006
Lupin FY 2006-07 Q2 Net Profit up by 29% at Rs.583 mn
Mr. Edward R. Roberts joins Lupin Board


September 2006
Lupin and Dafra decide not to pursue their MoU
Lupin gets US FDA approval for Lisinopril-HCTZ Tablets
Lupin gets US FDA approval for Ceftriaxone 10gm vials


July 2006
Lupin receives DCGI approval to conduct Phase II Clinical Trials for Psoriasis NCE
Lupin FY 2006-07 Q1 Sales up by 33% at Rs.4.9 bn
Lupin gets USFDA approval for Meloxicam
Lupin announces District Court Ruling on Ramipril


June 2006
Lupin Receives final approval for Quinapril Tablets
Rajan Dutta joins Lupin as President, HRD
Lupin gets USFDA approval for Cefdinir Suspension


May 2006
Lupin to acquire 51% stake in Dafra
Lupin Announces Final FDA Approval of Cefdinir Capsules
Lupin joins hands with ItalFarmaco to launch Lupenox in India


April 2006
DST and Lupin join hands over Migraine and Psoriasis
Lupin receives US FDA Approval for Novel Formulation of Suprax® Suspension
Lupin finalizes patent sale agreement with Servier


March 2006
Lupin gets Marketing Approval for Cefpodoxime Proxetil in France
Lupin's US Subsidiary Enters Into Collaboration to Promote Atopiclair™ Nonsteroidal Cream to Pediatricians in the U.S


February 2006
Lupin-Aspen sign Joint Venture
Lupin LCTL Divestment
Lupin to Reorganise Sale Structure for Suprax
Lupin sells Intellectual Property on Perindopril to Servier
Lupin receives US FDA approval for Sertraline


January 2006
Lupin and Aspen decide not to pursue their MOU
Lupin FY 2006-07 Q3 Net Profit up by 27% at Rs.560 mn
Lupin gets tentative US FDA approval for Sertraline